CROs, tools and service companies at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

29 CROs, tools and service companies are at ENA 2026 — 46 presentations on the program and 12 with a booth in the exhibit hall. Most represented: Crown Bioscience (5 on the program), Biocytogen (3 on the program), Oncolines (2 on the program). 19 of them have their own page in this guide. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–11 of 29 organizations

Organization	ENA 2026 Attendance
Crown Bioscience San Diego, CA
crownbio.com CROs & CDMOsExhibitor Preclinical oncology CRO offering patient-derived xenograft, organoid and syngeneic models plus translational and biomarker services.	Booth Exhibiting at Booth 30 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Developing Different Preclinical RAS Inhibitor Resistant Xenograft Models for Next-Generation Therapeutic Evaluation Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Integrated Organoid Screening Approaches Enable Preclinical Assessment of Targeted Protein Degrader Efficacy and Target Engagement Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models Characterization of a Panel of PDX Models Derived from c-MET Targeting ADCs Pretreated Colorectal Cancer Patients for Therapeutic Evaluation Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models Establishing Preclinical Mouse Models for Translational Cancer Cachexia Research Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models End-to-end in vitro and in vivo evaluation of radiopharmaceuticals in patient-derived models Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Benchmarking Multiple Comparison Procedures for Patient-Derived Xenograft Tumor-Volume Studies: Toward Statistically Justified and Ethically Grounded Study Design Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models PDX-Derived Organoids Demonstrate High Concordance with In Vivo Responses Across KRAS Inhibitors and Antibody-Drug Conjugates Preclinical models
Biocytogen Beijing, China
biocytogen.com CROs & CDMOsExhibitor Provides humanized mouse models, preclinical pharmacology and antibody discovery, and develops its own antibody and ADC candidates.	Booth Exhibiting at Booth 23 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors ADCs & radioligands Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology BCG024: A Novel DLL3×CD3×4-1BB Trispecific T Cell Engager Enhances T Cell Persistence and Functionality in Preclinical Models Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models The B-hCRBN Mice Model Facilitates PROTACs Studies Based on CRBN Ligands Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Animal Models Utilizing a Humanized CD8 Mouse Model for Non-clinical Studies of Cancer Immunotherapy Preclinical models
Oncolines Oss, Netherlands
oncolines.com CROs & CDMOs Precision medicine services company profiling cancer drugs across large cell line panels.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Insights into resistance mechanisms against antibody-drug conjugates using large cancer cell panel profiling ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Characterization and targeting of adaptive KRASG12C inhibitor resistance through large-scale drug combination screening Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Molecular glue stabilization of the β-catenin/14-3-3 interaction as a novel strategy to modulate Wnt signaling Targeted agents
WuXi AppTec Shanghai, China
wuxiapptec.com CROs & CDMOsExhibitor Contract research, development and manufacturing organization offering drug discovery, in vivo pharmacology, testing and manufacturing services.	Booth Exhibiting at Booth 9 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Breaking through ADC resistance: generating TOP1 mutation cancer model and evaluating next generation ADCs ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Divergent mechanisms of acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib in KRAS mutant cancer Targeted agents
Evotec Hamburg, Germany
evotec.com CROs & CDMOs Drug discovery and development partner offering integrated research services from target identification to preclinical studies.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Screening 3D patient-derived cancer models for target validation and drug discovery Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Tumour immunology and inflammation Quantifying Immunological Synapse to Optimize Immune Cell Engagers and Cancer Immunotherapies Immuno-oncology
Urosphere Toulouse, France
urosphere.com CROs & CDMOs Preclinical contract research company offering urology and oncology models, including patient-derived xenografts and organoids.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Patient-derived PDX and organoid models reveal distinct molecular mechanisms of acquired resistance to olaparib and enfortumab vedotin in genitourinary cancers Biomarkers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Matched Patient-Derived Xenografts and Organoids Faithfully Preserve the Molecular Landscape and Drug Response of Breast Cancer Preclinical models
ICE Bioscience Beijing, China
ice-biosci.com CROs & CDMOsExhibitor Contract research organization offering target validation, compound screening and preclinical drug discovery services.	Booth Exhibiting at Booth 10 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Characterization and Overcoming of KRAS-Targeted Therapy Resistance in Resistant Cancer Cell Lines Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Design ER-BRD4 RIPTAC: Bridging Target Engagement to a Target-Dependent Therapeutic Window Drug design Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Design AR–BRD4 RIPTAC Induces Expression-Dependent Ternary Complex Formation to Achieve Tumor-Selective Target Engagement in Prostate Cancer Drug design
XenTech Évry, France
xentech.eu CROs & CDMOsExhibitor Preclinical contract research company specialising in patient-derived xenograft models, including models of acquired resistance to targeted therapies.	Booth Exhibiting at Booth 8 Wed, Nov 1812–7pmThu, Nov 199am–5:30pmFri, Nov 209am–3pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Breast cancer patient-derived xenograft models reveal convergent mechanisms of acquired resistance to olaparib through homologous recombination restoration Preclinical models Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models Patient-Derived Models Reveal Distinct Molecular Mechanisms of Acquired Resistance to Trastuzumab Deruxtecan in Triple-Negative Breast Cancer Preclinical models
BostonGene Waltham, MA
bostongene.com Tools, data & diagnostics AI-driven molecular and immune profiling of tumours for precision oncology and drug development.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Molecular profiling RNA-seq analysis enhances detection of clinically relevant oncogene splice isoforms in solid tumors Genomics Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Cancer Genomics RNA-seq-based expression signature enhances clinical detection of retinoblastoma transcriptional corepressor 1 (RB1) loss in whole-exome sequencing Genomics
Concr London, UK
concr.co Tools, data & diagnostics Builds AI digital-twin models of cancer patients to predict treatment response for trials and drug development.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Artificial Intelligence Multi-modal Digital Twin Model Outperforms Conventional Biomarker Stratification in Pancreatic Cancer AI Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Artificial Intelligence Multimodal Digital Twins Predict Chemotherapy Backbone Response to Uncover Immunotherapy Benefit in TNBC AI
IRBM Pomezia, Italy
irbm.com CROs & CDMOs Contract drug discovery company offering medicinal chemistry, biology and preclinical services.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Transcriptomic profiling defines responders to brain-penetrant SHP2 inhibition in glioblastoma Biomarkers Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Preclinical Models C3PO: Complex 3D Patient Organoids for Preclinical Drug Testing in Brain Tumors Preclinical models